Hang Seng Medical ETF (513060) rose 3%, Baiji Shenzhou rose over 12%

In the morning, Hang Seng Medical ETF (513060) opened the market and increased by 3%.Among the ingredients stocks, Baiji Shenzhou rose over 12%, Rongchang Biological-B rose more than 9%, and Huang Medicine rose more than 7%.%, Aikang Medical, Ding Ding Medical-B, Qiming Medical-B and other individual stocks have risen.As of press time, the turnover of Hang Seng Medical ETF (513060) exceeded 900 million.

On the news, Baiji Shenzhou announced the independent research and development of PD-1 monoclonal anti-anti-anti-drug drugs for the Ratchale & nbsp; 306 research) data.Or metastatic esophageal squamous cell carcinoma has refreshed the longest survival record, and the median total survival (MOS) reached 17.2 months.

East Asia Qianhai Securities stated that the relevant policies are densely introduced. It can be seen that the country's support for the high -quality development of the innovative pharmaceutical industry is very clear. In addition, the huge domestic demand for innovative medicine in China, we think that the potential of this sector is greater.The configuration of the innovative pharmaceutical sector is still cost -effective.

- END -